PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Subdivisions of Program Areas, these track general higher level sub-classifications of expenditure.
Subdivisions of Major categories, these are the most detailed expenditure data.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2008
ACTIVITY UNCHANGED FROM FY 2008
Activities funded with Track 1 funding is integrated with the local funding, and this comprehensive program
(including progress and planned activities) are contained in the local funding COP entry.
AIDSRelief implements a comprehensive HIV care and treatment program in South Africa that is funded
with Track 1 central funding, as well as South Africa COP funding. The activities do not differ across the
funding mechanisms, and this entry is thus a repeat of the South Africa COP entry. All targets are reflected
in the South Africa COP entry.
Activities are implemented to support provision of quality ARV services under the comprehensive
antiretroviral treatment (ART) program carried out by Catholic Relief Services (CRS) in 25 sites in 8
provinces in South Africa. Major emphasis will be on human capacity development and local organization
capacity building. The target population includes people affected by HIV and AIDS as well as higher risk
populations such as migrant workers and refugees.
AIDSRelief (the Consortium led by Catholic Relief Services) has received Track 1 funding since FY 2004 to
rapidly scale up antiretroviral therapy (ART) in 9 countries, including South Africa. Since FY 2005, South
Africa in-country funding was received to supplement central funding. The activity is implemented through
two major in-country partners, Southern African Catholic Bishops' Conference (SACBC) and Institute for
Youth Development South Africa (IYD-SA).
ACTIVITIES AND EXPECTED RESULTS:
With funding provided in FY 2008 AIDSRelief will continue implementing the activities in support of the
South African Government (SAG) national ARV rollout. In the interest of maximizing available funds the
focus will be on strengthening the existing sites providing services rather than on assessing and activating
new sites. Utilizing technical assistance from AIDSRelief staff members and South African experts, ongoing
support and guidance will be provided to sites in form of appropriate refresher medical training courses,
patient tracking and reporting, monitoring and evaluation mechanisms and other necessary support.
ARV services will be provided through the 25 sites to ARV patients through clinic-based and home-based
activities to optimize quality of life for HIV-infected clients and their families. All the relevant healthcare
providers and administrative support staff at the sites will be trained to implement the ART program, using
government-approved training curricula. Staff who have already received initial training will undergo
refresher courses (either in-house or external), coupled with exchange of training courses and materials
between sites with active support from the local training provider, Kimera training center. Treatment
adherence training is provided to all patients who are enrolled on the ART program.
In most sites home-based care networks will follow up and support patients. This follow-up is conducted
through direct visits to patients through the extensive home-based care outreach at the SACBC sites, while
IYD-SA sites follow up through means of telephonic contact in most cases. In case the patient cannot be
reached, a "treatment buddy" is contacted to inquire the whereabouts of the patients who did not come back
for the monthly drug package. Inevitably, some patients become lost-to-follow-up in spite of all the efforts to
locate them, due to migrating populations and illegal immigrants served by the program. This number
currently stands at less than 4% of the patients ever enrolled on the program.
Each site ensures that HIV-infected patients are screened for tuberculosis (TB) prior to placing them on
antiretroviral treatment, and are referred to TB treatment if they tested positive. Screening and testing for TB
is conducted in a number of different ways, and these testing methods are specific to each site. While
screening is conducted by a medical professional at each of the sites, in most cases patients are referred to
the nearby SAG medical facility for TB testing and are only enrolled in antiretroviral treatment once they
have completed two months of TB treatment, or have been found not to have active TB.
PEPFAR funding will also be used to support laboratory services, which are outsourced to a private
provider, Toga Laboratories (a new PEPFAR partner since FY 2007). A courier service collects blood that is
drawn at each site, and delivers these samples to the laboratories. Results are e-mailed or faxed back to
the site within 48 hours of the laboratory receiving the blood samples.
The program is designed to improve each site's capacity to implement the national ART program in the long
-term, and to strengthen clinical, administrative, financial and strategic information systems. Sites will be
assisted in developing appropriate policies and protocols and in setting up sound financial and strategic
information systems. Each site will also develop a unique community mobilization plan for the ART program
and implement it in collaboration with relevant community organizations and leaders. Many of the sites are
already involved in HIV and AIDS community mobilization activities and these will be linked to ART
services. These lessons learned will be of value to other partners working in the non-governmental
organization (NGO) sector.
All activities will continue to be implemented in close collaboration with the Department of Health HIV and
AIDS Unit and the respective provincial authorities to ensure coordination and information sharing, and this
will directly contribute to the success of the SAG's own rollout and the goals of PEPFAR. These activities
are also aimed at successful integration of AIDSRelief activities with those implemented by the South
African Government, thus ensuring long-term sustainability.
All sites operate under the terms of a Memorandum of Understanding (MOU) with the provincial Department
of Health in which they operate, observing the national and provincial treatment protocols. There is a
concerted effort at each site to ensure sustainability by having the SAG provide antiretroviral drugs, or by
Activity Narrative: down referring stable patients into the SAG's primary healthcare clinics after providing training for the SAG
clinic staff. St. Mary's Hospital, which accounts for more than a third of patient numbers, has already been
accredited as a SAG rollout site. Sinosizo receives drugs from the National Department of Health due to its
status as a down referral clinic for Stanger Hospital, and at a further two sites, Centocow and Bethal, all
patients already receive drugs via the SAG rollout. Monthly statistics are shared with the South African
National Department of Health, as well as with relevant provincial health departments in provinces where
AIDSRelief implements the program.
There is a concerted effort to include men and children in the program, and all sites have specific plans to
increase enrolment, including couple counseling and using a family-based approach. Although there is no
specific PMTCT program, eligible pregnant women are provided with triple therapy to ensure maximum viral
suppression to prevent the transmission to the baby. Newborn babies are provided with monotherapy after
birth. AIDSRelief sites are encouraged to provide babies with cotrimoxazole after 4-6 weeks of life, and
PCR testing is conducted when relevant. Mothers are encouraged to use safe feeding practices as
appropriate to individual circumstances. Most sites have clinic-based gardens to assist with nutrition
programs, and several sites provide nutrition supplements, as per South African treatment guidelines. All
sites provide ART access to non-South Africans, including refugees. Some of the AIDSRelief sites also
receive PEPFAR and other funding through different sources for the provision of OVC care. The
overlapping of these services provides OVC with access to both care and treatment services provided
under the program.
In terms of the continuous qualitative review of the program, the annual clinical evaluation is done on
available patient data by two South African ART experts, who not only evaluate the data within the program
but also compare it to other large resource-limited programs, such as the program in Khayelitsha.
Even though prevention is not a specific program activity of the overall program, it is promoted through
provision of information to patients regarding HIV and prevention of spreading the virus (prevention for
positives). Secondly, skills training is provided to vulnerable populations, empowering them to make safer
choices about their lives. Additionally, AB messages are shared with the target population, as well as
accurate information regarding condoms is provided.
The CRS treatment program supports the PEPFAR goal of treating 2 million people with antiretroviral drugs.
New/Continuing Activity: Continuing Activity
Continuing Activity: 13716
Continued Associated Activity Information
Activity Activity ID USG Agency Prime Partner Mechanism Mechanism ID Mechanism Planned Funds
System ID System ID
13716 3286.08 HHS/Health Catholic Relief 6581 2792.08 Track 1 $4,372,523
7484 3286.07 HHS/Health Catholic Relief 4437 2792.07 Track 1 $4,372,523
3286 3286.06 HHS/Health Catholic Relief 2792 2792.06 Track 1 $4,461,580
Human Capacity Development
Estimated amount of funding that is planned for Human Capacity Development $1,600,000
Public Health Evaluation
Food and Nutrition: Policy, Tools, and Service Delivery
Food and Nutrition: Commodities
Activities funded with Track 1 funding are integrated with the local funding, and this comprehensive program
(including progress and planned activities) is contained in the local funding COP entry.
Activities are implemented to support procurement of antiretroviral (ARV) drugs under the comprehensive
ART program carried out by Catholic Relief Services (CRS) in 25 sites. Coverage extends to eight
provinces in South Africa (excluding the Western Cape). The emphasis areas are human capacity
development and local organization capacity building. The target population includes people affected by HIV
and AIDS as well as higher risk populations such as migrant workers and refugees.
AIDSRelief (the Consortium led by Catholic Relief Services) received Track 1 funding in FY 2004 to rapidly
scale-up antiretroviral therapy (ART) in nine countries, including South Africa. Since FY 2005, in-country
funding has supplemented Track 1 funding, and this will continue in FY 2008. The activity is implemented
through two major in-country partners, Southern African Catholic Bishops' Conference (SACBC) and the
Institute for Youth Development South Africa (IYD-SA).
With funding provided in FY 2008, AIDSRelief will continue implementing the activities in support of the
South African Government (SAG) national ART rollout. In the interest of maximizing available funds the
focus will be placed on strengthening the existing sites' provision of services rather than on assessing and
activating new sites. Utilizing technical assistance from AIDSRelief staff members and South African
experts, ongoing support and guidance will be provided to sites in the form of appropriate refresher medical
training courses, patient tracking and reporting, monitoring and evaluation mechanisms and other
ARV drugs are provided to all qualifying HIV patients who present at the sites, irrespective of their age,
gender, nationality, religious or political beliefs. The access to non-South Africans is particularly significant,
as the public sector rollout program is restricted to South African and legal refugees and asylum seekers.
However, South Africa has a large displaced population, including economic migrants who do not have
South African identity documentation. Historically, about 90% of adults and 10% of children with HIV have
been receiving ARV drugs through the 25 partner sites.
ARV drugs purchased will be used by the 25 sites to treat ARV patients through clinic-based and home-
based activities aimed at optimizing quality of life for HIV-infected clients and their families. For most of the
25 sites, ARV drugs are currently being purchased centrally through a Johannesburg-based pharmaceutical
company, and delivered via courier to the field sites monthly on a patient-named basis. CRS is billed once a
month for all site deliveries after verification of drugs delivered to each site. The opportunity of accessing
preferential cost drugs is being utilized through cooperation with GlaxoSmithKline where available. Although
the AIDSRelief sites have not experienced stock-outs in significant volume, they have been experienced on
a limited number of occasions. Efforts to address or prevent such occurrences in the future include
substitution by a more expensive drug on stock (all approved by the appropriate regulatory authorities of the
host country and the donor).
Generic medications purchased comply with the USG PEPFAR Task Force requirement of FDA approval as
well as approval from the Medicines Control Council of South Africa.
All activities will continue to be implemented in close collaboration with the South African Government's HIV
and AIDS Unit and the respective provincial authorities to ensure coordination and information sharing,
directly contributing to the success of the South African Government's own rollout and the goals of the
President's Emergency Plan. These activities are also aimed at successful integration of AIDSRelief
activities into those implemented by the South African government, thus ensuring long-term sustainability.
All sites operate in terms of a Memorandum of Understanding (MOU) with the provincial Department of
Health in which they operate, observing the national and provincial treatment protocols. There is a
concerted effort at each site to ensure sustainability by either having the SAG provide antiretroviral drugs, or
by down referring stable patients in to the public primary healthcare clinics after providing training for the
SAG clinic staff. St. Mary's Hospital, which accounts for more than a third of patient numbers, has already
been accredited as a SAG rollout site. Sinosizo is receiving drugs from Department of Health due to its
status as a down referral clinic for Stanger Hospital. At Centocow and Bethal, all patients are already
receiving drugs through the SAG rollout.
In terms of the actual drug procurement, AIDSRelief in South Africa has a centralized procurement system
of ARV drugs, which already provides the economies of scale in terms of drug pricing to the extent possible
(outside of the SAG-mandated single exit price). This centralized procurement system buys drugs in
volume, and keeps sufficient stock levels to supply the AIDSRelief sites with drugs and ensure no stock-
outs occur. The centralized procurement system also manages losses due to expiry of the drugs, and
ensures compliance with FDA and MCC (Medicines Control Council of South Africa) requirements. Each
patient has their 6-month repeat prescription originally assigned by the doctor and then dispensed by the
pharmaceutical supplier, which is revised where necessary (in line with SAG guidelines).
Activity Narrative: In terms of monitoring of the program, the majority of the AIDSRelief sites are utilizing the centrally-based
laboratory services provider Toga (a PEPFAR prime partner) that conducts blood tests (CD4, viral load etc.)
for the sits, using the courier service available in country to deliver the blood samples, and reporting back to
the sites on the results through either e-mail or an online electronic reporting system setup by the
Laboratory services provider.
Due to good existing infrastructure in South Africa, AIDSRelief sites are able to perform viral load and CD4
tests once every 6 weeks, to monitor the treatment progress and possible failure on the individual patient
level. These analyses are conducted by each of the AIDSRelief sites, using the data provided by the
Laboratory services provider, as part of the clinical management of the patients. The majority of the
AIDSRelief sites also use hand-held lactate meters (provided for free by the Laboratory services provider) to
screen for hyperlactatemia, which is the most common severe side effect of patients who have been on
treatment for prolonged periods of time.
Feedback on program level of the progress and viral suppression is regularly provided by a clinical expert at
the Desmond Tutu HIV Foundation, using the laboratory data provided by Toga Labs on patients whose
blood was tested through their facilities.
FY 2008 COP activities will be expanded to include increased collaboration with the SAG to ensure long-
term sustainability of the program, through different arrangements which vary from one Province to another.
These include the transfer of "stable" patients (on ART for 6 months or longer) to public sector health
facilities, and then enrolling additional patients at the AIDSRelief partner site. Other options include
provision of free ARV and OI drugs and laboratory tests for SAG-accredited facilities run by AIDSRelief, or
those that are physically located on SAG-owned premises, thus allowing them to receive free drugs or
services. As in the case above, this allows the AIDSRelief sites to enroll additional patients on ART. Other
examples include provision of ARV drugs by the SAG, and home-based care and support and adherence
follow-up by the AIDSRelief-run partner site. All the different models of collaboration are individually
discussed with the provinces where the partner sites operate, and largely depend on specific needs and
operating environment of each treatment site and SAG authorities, but are designed to ultimately allow long-
term sustainability and success of the program.
Continuing Activity: 13715
Activity Activity ID USG Agency Prime Partner Mechanism Mechanism ID Mechanism Planned Funds
System ID System ID
13715 3287.08 HHS/Health Catholic Relief 6581 2792.08 Track 1 $3,191,217
7485 3287.07 HHS/Health Catholic Relief 4437 2792.07 Track 1 $3,191,217
3287 3287.06 HHS/Health Catholic Relief 2792 2792.06 Track 1 $3,191,216